An AAN platform session featuring authors giving encore presentations of top abstracts previously presented at a subspecialty meeting.
- Invited Science: Headache
Top abstracts previously presented at the American Headache Society Annual Meeting will be presented by their authors in 20-minute platform presentations. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of headache with the overall goal of developing more effective prevention and treatment.
Monday, April 24 from 3:30 p.m. to 5:30 p.m.
Early Life Stress Increases Susceptibility to Cortical Spreading Depression and Anxiety in Rodents
3:30 p.m.-3:50 p.m.
Stuart Collins, PhD, Toledo, OH
Post-traumatic Headache Five Years after Traumatic Brain Injury
3:50 p.m.-4:10 p.m.
Sylvia M. Lucas, MD, PhD, Seattle, WA
Epidemiology of Migraine in Men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
4:10 p.m.-4:30 p.m.
Ann Scher, PhD, Bethesda, MD
Perspectives of Adolescents on the Burden of their Parent's Migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study
4:30 p.m.-4:50 p.m.
Richard B. Lipton, MD, FAAN, Bronx, NY
CRP and Migraine in Young Adults - Results from the Add Health Study
4:50 p.m.-5:10 p.m.
Gretchen E. Tietjen, MD, Toledo, OH
Altered Pupillary Light Responses in Migrainous Photophobia
5:10 p.m.-5:30 p.m.
Melissa M. Cortez, DO, Salt Lake City, UT
- Invited Science: Neuro-oncology
Top abstracts previously presented at the Society for Neuro-oncology Annual Meeting will be presented by their authors in 20-minute platform presentations. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of neuro-oncology with overall goal of developing more effective prevention and treatment.
Tuesday, April 25 from 1:00 p.m. to 3:00 p.m.
ACT IV: An International, Double-blind, Phase 3 Trial of Rindopepimut in Newly Diagnosed, EGFRvIIIexpressing Glioblastoma
1:00 p.m.-1:20 p.m.
Michael Weller, MD, Zurich, Switzerland
Targeting Carcinoma-astrocyte Gap Junctions in Brain Metastasis
1:20 p.m.-1:40 p.m.
Adrienne Boire, MD, New York, NY
Single-cell Profiling of Glioblastoma Biopsies Identifies a Family of Activating PDGF-receptor Deletions
1:40 p.m.-2:00 p.m.
Soeren Mueller, PhD, San Francisco, CA
Transformation of Tumor Endothelial Cells to Mesenchymal Stem Cell-like Cells Induces Therapy Resistance in Glioblastoma
2:00 p.m.-2:20 p.m.
Menggui Huang, PhD, Philadelphia, PA
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 (Durvalumab [DUR]) in Patient with Glioblastoma (GBM): Results For Cohort B (DUR Monotherapy), Bevacizumab (BEV) Naïve Patients with Recurrent GBM
2:20 p.m.-2:40 p.m.
David A. Reardon, MD, Boston, MA
Redefining the Cellular Architecture of Adult and Pediatric Glioblastomas Through Large-scale Singlecell Analyses
2:40 p.m.-3:00 p.m.
Mariella Filbin, MD, PhD, Boston, MA